309 related articles for article (PubMed ID: 15003647)
21. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli.
Theisen M; Vuust J; Gottschau A; Jepsen S; Høgh B
Clin Diagn Lab Immunol; 1995 Jan; 2(1):30-4. PubMed ID: 7719909
[TBL] [Abstract][Full Text] [Related]
22. Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs.
Bang G; Prieur E; Roussilhon C; Druilhe P
PLoS One; 2011; 6(12):e28165. PubMed ID: 22145028
[TBL] [Abstract][Full Text] [Related]
23. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria.
Dodoo D; Theisen M; Kurtzhals JA; Akanmori BD; Koram KA; Jepsen S; Nkrumah FK; Theander TG; Hviid L
J Infect Dis; 2000 Mar; 181(3):1202-5. PubMed ID: 10720556
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations.
Ramasamy R; Yasawardena S; Zomer A; Venema G; Kok J; Leenhouts K
Vaccine; 2006 May; 24(18):3900-8. PubMed ID: 16545511
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
26. Plasmodium chabaudi: immunogenicity of a highly antigenic glutamate-rich protein.
Wiser MF; Giraldo LE; Schmitt-Wrede HP; Wunderlich F
Exp Parasitol; 1997 Jan; 85(1):43-54. PubMed ID: 9024201
[TBL] [Abstract][Full Text] [Related]
27. Plasmodium falciparum MSP3 Exists in a Complex on the Merozoite Surface and Generates Antibody Response during Natural Infection.
Deshmukh A; Chourasia BK; Mehrotra S; Kana IH; Paul G; Panda A; Kaur I; Singh SK; Rathore S; Das A; Gupta P; Kalamuddin M; Gakhar SK; Mohmmed A; Theisen M; Malhotra P
Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29760216
[No Abstract] [Full Text] [Related]
28. Characterisation of two novel proteins from the asexual stage of Plasmodium falciparum, H101 and H103.
Pearce JA; Mills K; Triglia T; Cowman AF; Anders RF
Mol Biochem Parasitol; 2005 Feb; 139(2):141-51. PubMed ID: 15664649
[TBL] [Abstract][Full Text] [Related]
29. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth.
Chang SP; Gibson HL; Lee-Ng CT; Barr PJ; Hui GS
J Immunol; 1992 Jul; 149(2):548-55. PubMed ID: 1624802
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of polyepitope libraries assembled by epitope shuffling: an approach to the development of chimeric gene vaccination against malaria.
Cai QL; Wei F; Lin YH; Shao DD; Wang H
Vaccine; 2004 Nov; 23(2):267-77. PubMed ID: 15531046
[TBL] [Abstract][Full Text] [Related]
31. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro.
Theisen M; Soe S; Oeuvray C; Thomas AW; Vuust J; Danielsen S; Jepsen S; Druilhe P
Infect Immun; 1998 Jan; 66(1):11-7. PubMed ID: 9423833
[TBL] [Abstract][Full Text] [Related]
32. Passive transfer of Plasmodium falciparum MSP-2 pseudopeptide-induced antibodies efficiently controlled parasitemia in Plasmodium berghei-infected mice.
Martínez PA; Yandar N; Lesmes LP; Forero M; Pérez-Leal O; Patarroyo ME; Lozano JM
Peptides; 2009 Feb; 30(2):330-42. PubMed ID: 19071172
[TBL] [Abstract][Full Text] [Related]
33. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.
Patarroyo ME; Amador R; Clavijo P; Moreno A; Guzman F; Romero P; Tascon R; Franco A; Murillo LA; Ponton G
Nature; 1988 Mar; 332(6160):158-61. PubMed ID: 2450281
[TBL] [Abstract][Full Text] [Related]
34. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
[TBL] [Abstract][Full Text] [Related]
35. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.
Soe S; Theisen M; Roussilhon C; Aye KS; Druilhe P
Infect Immun; 2004 Jan; 72(1):247-52. PubMed ID: 14688102
[TBL] [Abstract][Full Text] [Related]
36. Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3.
Osier FH; Polley SD; Mwangi T; Lowe B; Conway DJ; Marsh K
Parasite Immunol; 2007 Aug; 29(8):387-94. PubMed ID: 17650180
[TBL] [Abstract][Full Text] [Related]
37. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
[TBL] [Abstract][Full Text] [Related]
38. Distribution of IgG subclass antibodies specific for Plasmodium falciparum glutamate-rich-protein molecule in sickle cell trait children with asymptomatic infections.
Matondo Maya DW; Mavoungou E; Deloron P; Theisen M; Ntoumi F
Exp Parasitol; 2006 Feb; 112(2):92-8. PubMed ID: 16356497
[TBL] [Abstract][Full Text] [Related]
39. [Preparation and characterization of monoclonal antibodies against erythrocyte-binding antigen 175 of Plasmodium falciparum].
Hao WB; Hong YH; Sun XM; Ning Y; Zhang DM; Pan WQ; Li M
Di Yi Jun Yi Da Xue Xue Bao; 2005 Sep; 25(9):1169-71. PubMed ID: 16174591
[TBL] [Abstract][Full Text] [Related]
40. Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes.
Sakamoto H; Takeo S; Maier AG; Sattabongkot J; Cowman AF; Tsuboi T
Vaccine; 2012 Mar; 30(11):1972-80. PubMed ID: 22248820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
